Ayalew Tefferi

List of Publications by Citations

815 papers	43,364 citations	107 h-index	191 g-index
841 ext. papers	49,740 ext. citations	5.6 avg, IF	7.91 L-index

#	Paper	IF	Citations
815	The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood*, **2009**, 114, 937-51	2.2	3222
814	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*, **2005**, 7, 387-97	24.3	2353
813	Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. *New England Journal of Medicine*, **2010**, 363, 1117-27	59.2	906
812	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. *Blood*, **2009**, 113, 2895-901	2.2	905
811	Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. *Leukemia*, **2008**, 22, 14-22	10.7	780
810	DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *Journal of Clinical Oncology*, **2011**, 29, 392-7	2.2	677
809	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood*, **2010**, 115, 1703-8	2.2	645
808	Myelofibrosis with myeloid metaplasia. *New England Journal of Medicine*, **2000**, 342, 1255-65	59.2	640
807	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *Journal of Clinical Oncology*, **2011**, 29, 761-70	2.2	589
806	Myelodysplastic syndromes. *New England Journal of Medicine*, **2009**, 361, 1872-85	59.2	527
805	Mutations and prognosis in primary myelofibrosis. *Leukemia*, **2013**, 27, 1861-9	10.7	520
804	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. *Leukemia*, **2010**, 24, 1128-38	10.7	435
803	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood*, **2014**, 124, 2507-13; quiz 2615	2.2	424
802	Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. *Journal of Clinical Oncology*, **2011**, 29, 1356-63	2.2	402
801	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. *Blood*, **2009**, 113, 5727-36	2.2	399
800	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. *Leukemia*, **2013**, 27, 1874-81	10.7	389
799	CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. *Leukemia*, **2014**, 28, 1472-7	10.7	381

798	Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. *British Journal of Haematology*, **2005**, 128, 275-90	4.5	371
797	Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. *Journal of Clinical Oncology*, **2011**, 29, 3179-84	2.2	355
796	Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. *Leukemia*, **2008**, 22, 437-8	10.7	355
795	TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. *Leukemia*, **2009**, 23, 905-11	10.7	351
794	Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). *Blood*, **2012**, 120, 5128-33; quiz 5252	2.2	340
793	Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. *Blood*, **2011**, 117, 5857-9	2.2	295
792	Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. *Mayo Clinic Proceedings*, **2006**, 81, 159-66	6.4	269
791	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. *Leukemia*, **2010**, 24, 1302-9	10.7	266
790	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia*, **2018**, 32, 1057-1069	10.7	263
789	JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. *British Journal of Haematology*, **2005**, 131, 208-13	4.5	257
788	A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. *Blood*, **2003**, 101, 2534-41	2.2	255
787	Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. *American Journal of Hematology*, **1999**, 61, 10-5	7.1	251
786	Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. *Mayo Clinic Proceedings*, **2003**, 78, 1223-33	6.4	245
785	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncology*, **2015**, 1, 643-51	13.4	242
784	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. *Leukemia*, **2008**, 22, 1299-307	10.7	239
783	Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. *Leukemia*, **2008**, 22, 756-61	10.7	229
782	Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. *Leukemia*, **2007**, 21, 1960-3	10.7	226
781	Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. *Blood*, **2000**, 95, 2226-2233	2.2	224

780	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. *Journal of Clinical Oncology*, **2018**, 36, 310-318	2.2	224
779	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer Journal*, **2018**, 8, 15	7	221
778	Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. *Leukemia*, **2009**, 23, 900-4	10.7	221
777	A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. *New England Journal of Medicine*, **2015**, 373, 908-19	59.2	219
776	Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. *Leukemia*, **2009**, 23, 1343-5	10.7	219
775	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood*, **2013**, 122, 1395-8	2.2	218
774	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. *Blood*, **2011**, 118, 401-8	2.2	215
773	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. *Leukemia*, **2014**, 28, 1804-10	10.7	213
772	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. *Leukemia*, **2014**, 28, 1494-500	10.7	211
771	Pathogenesis of myelofibrosis with myeloid metaplasia. *Journal of Clinical Oncology*, **2005**, 23, 8520-30	2.2	211
770	Lenalidomide therapy in myelofibrosis with myeloid metaplasia. *Blood*, **2006**, 108, 1158-64	2.2	211
769	Eosinophilia: secondary, clonal and idiopathic. *British Journal of Haematology*, **2006**, 133, 468-92	4.5	196
768	Myeloproliferative Neoplasms: A Contemporary Review. *JAMA Oncology*, **2015**, 1, 97-105	13.4	195
767	Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?. *Blood*, **1994**, 84, 1620-1627	2.2	194
766	CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. *Leukemia*, **2013**, 27, 1870-3	10.7	187
765	The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. *Cancer*, **2006**, 106, 631-5	6.4	187
764	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. *Leukemia*, **2014**, 28, 2206-12	10.7	186
763	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. *Leukemia*, **2014**, 28, 1774-83	10.7	184

762	The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. *Cancer*, **2009**, 115, 3842-7	6.4	180
761	The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. *Leukemia*, **2014**, 28, 485-96	10.7	179
760	Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. *Leukemia*, **2011**, 25, 1200-2	10.7	178
759	A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. *Blood*, **2012**, 120, 1197-201	2.2	172
758	Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. *Mayo Clinic Proceedings*, **2011**, 86, 1188-91	6.4	172
757	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. *Leukemia*, **2015**, 29, 2126-33	10.7	171
756	Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. *British Journal of Haematology*, **2001**, 115, 619-21	4.5	169
755	An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. *Leukemia*, **2014**, 28, 1407-13	10.7	167
754	Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. *American Journal of Hematology*, **2015**, 90, 162-73	7.1	166
753	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. *Blood*, **2012**, 119, 569-72	2.2	164
752	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Advances*, **2016**, 1, 21-30	7.8	163
751	Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. *Leukemia*, **2007**, 21, 270-6	10.7	161
750	Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. *Seminars in Thrombosis and Hemostasis*, **2007**, 33, 313-20	5.3	157
749	LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. *Leukemia*, **2010**, 24, 1713-8	10.7	156
748	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. *Leukemia*, **2013**, 27, 1504-10	10.7	151
747	Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. *Leukemia*, **2011**, 25, 82-8	10.7	150
746	Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. *Cancer*, **2006**, 107, 361-70	6.4	148
745	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. *American Journal of Hematology*, **2014**, 89, E121-4	7.1	145

744	One thousand patients with primary myelofibrosis: the mayo clinic experience. *Mayo Clinic Proceedings*, **2012**, 87, 25-33	6.4	137
743	Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. *American Journal of Hematology*, **2009**, 84, 790-4	7.1	135
742	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. *Blood*, **2010**, 116, 2857-8	2.2	133
741	DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. *Leukemia*, **2011**, 25, 1219-20	10.7	131
740	Treatment of systemic mast-cell disease with cladribine. *New England Journal of Medicine*, **2001**, 344, 307-9	59.2	130
739	Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2017**, 92, 94-108	7.1	129
738	Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. *Blood Cancer Journal*, **2015**, 5, e366	7	129
737	JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. *Blood*, **2012**, 119, 2721-30	2.2	129
736	IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. *Leukemia*, **2012**, 26, 475-80	10.7	129
735	Oncogenes in myeloproliferative disorders. *Cell Cycle*, **2007**, 6, 550-66	4.7	129
734	Long-term use of anagrelide in young patients with essential thrombocythemia. *Blood*, **2001**, 97, 863-6	2.2	129
733	SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. *Blood*, **2012**, 120, 4168-71	2.2	128
732	Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?. *Blood*, **1994**, 84, 1620-1627	2.2	126
731	Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. *American Journal of Hematology*, **2012**, 87, 285-93	7.1	125
730	Chronic natural killer cell lymphocytosis: a descriptive clinical study. *Blood*, **1994**, 84, 2721-2725	2.2	125
729	Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. *Blood Cancer Journal*, **2015**, 5, e369	7	123
728	MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. *Journal of Clinical Oncology*, **2018**, 36, 1769-1770	2.2	123
727	Long-term outcome of treatment with ruxolitinib in myelofibrosis. *New England Journal of Medicine* , **2011**, 365, 1455-7	59.2	121

726	Targeted deep sequencing in primary myelofibrosis. *Blood Advances*, **2016**, 1, 105-111	7.8	120
725	Myelodysplastic syndromes: Contemporary review and how we treat. *American Journal of Hematology*, **2016**, 91, 76-89	7.1	119
724	Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. *American Journal of Hematology*, **2019**, 94, 133-143	7.1	119
723	Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. *Leukemia*, **2014**, 28, 1568-70	10.7	118
722	LNK mutations in JAK2 mutation-negative erythrocytosis. *New England Journal of Medicine*, **2010**, 363, 1189-90	59.2	118
721	Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. *Mayo Clinic Proceedings*, **2010**, 85, 158-64	6.4	118
720	Polycythemia vera: a comprehensive review and clinical recommendations. *Mayo Clinic Proceedings*, **2003**, 78, 174-94	6.4	118
719	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. *Leukemia*, **2018**, 32, 1631-1642	10.7	117
718	Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. *British Journal of Haematology*, **1998**, 103, 505-11	4.5	115
717	Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. *Blood*, **2008**, 111, 2785-9	2.2	115
716	Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. *Leukemia*, **2012**, 26, 716-9	10.7	112
715	Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. *American Journal of Hematology*, **2013**, 88, 201-6	7.1	112
714	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. *Leukemia*, **2012**, 26, 101-5	10.7	112
713	Risk factors for leukemic transformation in patients with primary myelofibrosis. *Cancer*, **2008**, 112, 2726-32	6.4	112
712	FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. *Leukemia Research*, **2006**, 30, 965-70	2.7	110
711	A long-term retrospective study of young women with essential thrombocythemia. *Mayo Clinic Proceedings*, **2001**, 76, 22-8	6.4	110
710	How to interpret and pursue an abnormal complete blood cell count in adults. *Mayo Clinic Proceedings*, **2005**, 80, 923-36	6.4	109
709	Myeloproliferative neoplasms: A decade of discoveries and treatment advances. *American Journal of Hematology*, **2016**, 91, 50-8	7.1	108

708	Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. *Blood*, **1990**, 75, 1770-1773	2.2	107
707	Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. *Leukemia*, **2007**, 21, 1827-8	10.7	106
706	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. *Blood*, **2014**, 124, 2465-6	2.2	105
705	JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. *Leukemia*, **2011** , 25, 218-25	10.7	105
704	How I treat myelofibrosis. *Blood*, **2011**, 117, 3494-504	2.2	105
703	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. *American Journal of Hematology*, **2014**, 89, 1111-5	7.1	104
702	Masked polycythemia vera (mPV): results of an international study. *American Journal of Hematology* , **2014**, 89, 52-4	7.1	103
701	Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. *Nature Reviews Clinical Oncology*, **2009**, 6, 627-37	19.4	102
700	The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. *Mayo Clinic Proceedings*, **2005**, 80, 947-58	6.4	101
699	Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2016**, 91, 1262-1271	7.1	100
698	JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. *Leukemia*, **2010**, 24, 105-9	10.7	99
697	Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities [see comments]. *Blood*, **1996**, 87, 3000-3006	2.2	99
696	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. *Nature Medicine*, **2015**, 21, 1473-80	50.5	97
695	Thalidomide treatment in myelofibrosis with myeloid metaplasia. *British Journal of Haematology*, **2002**, 117, 288-96	4.5	97
694	Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2013**, 88, 507-16	7.1	92
693	Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. *Mayo Clinic Proceedings*, **2005**, 80, 75-83	6.4	91
692	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. *Blood Cancer Journal*, **2015**, 5, e333	7	89
691	Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2013**, 88, 141-50	7.1	89

690	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. *Blood*, **2013**, 121, 2393-401	2.2	89
689	Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. *American Journal of Hematology*, **2018**, 93, 1551-1560	7.1	85
688	Anemia in adults: a contemporary approach to diagnosis. *Mayo Clinic Proceedings*, **2003**, 78, 1274-80	6.4	84
687	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2016**, 6, e385	7	83
686	The complete evaluation of erythrocytosis: congenital and acquired. *Leukemia*, **2009**, 23, 834-44	10.7	83
685	SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. *Leukemia*, **2012**, 26, 1135-7	10.7	81
684	Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. *Blood*, **2002**, 99, 2627	2.2	81
683	Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2016**, 6, e393	7	80
682	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. *Blood*, **2014**, 124, 3021-3	2.2	80
681	A single institutional experience with 43 pregnancies in essential thrombocythemia. *European Journal of Haematology*, **2001**, 66, 152-9	3.8	80
680	Calreticulin mutations and long-term survival in essential thrombocythemia. *Leukemia*, **2014**, 28, 2300-3	10.7	79
679	Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. *Blood*, **2001**, 98, 483-5	2.2	79
678	The 5q- syndrome: a single-institution study of 43 consecutive patients. *Blood*, **1993**, 81, 1040-1045	2.2	79
677	Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. *Blood Cancer Journal*, **2015**, 5, e337	7	77
676	WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. *Leukemia*, **2005**, 19, 313-7	10.7	77
675	Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. *Leukemia*, **2016**, 30, 889-96	10.7	76
674	A long-term study of patients with chronic natural killer cell lymphocytosis. *British Journal of Haematology*, **1999**, 106, 960-6	4.5	76
673	SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. *Leukemia*, **2013**, 27, 2100-2	10.7	75

672	Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. *British Journal of Haematology*, **2014**, 165, 273-86	4.5	74
671	Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. *European Journal of Haematology*, **2009**, 82, 350-3	3.8	74
670	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. *Blood*, **2012**, 119, 2239-41	2.2	73
669	Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. *Leukemia Research*, **2007**, 31, 1503-9	2.7	73
668	Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. *British Journal of Haematology*, **2002**, 118, 813-6	4.5	73
667	Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. *American Journal of Hematology*, **2018**, 93, 824-840	7.1	73
666	Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. *American Journal of Hematology*, **2016**, 91, 390-4	7.1	72
665	Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2014**, 89, 915-25	7.1	72
664	WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. *Leukemia*, **2010**, 24, 1283-9	10.7	72
663	Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. *Blood Reviews*, **2001**, 15, 121-31	11.1	72
662	The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. *Blood Reviews*, **2016**, 30, 453-459	11.1	70
661	JAK and MPL mutations in myeloid malignancies. *Leukemia and Lymphoma*, **2008**, 49, 388-97	1.9	70
660	Acute leukemia during pregnancy: a single institutional experience with 17 cases. *Leukemia and Lymphoma*, **2001**, 41, 571-7	1.9	69
659	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. *Leukemia*, **2018**, 32, 1200-1210	10.7	68
658	A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. *Blood Cancer Journal*, **2015**, 5, e335	7	67
657	The effects of anagrelide on human megakaryocytopoiesis. *British Journal of Haematology*, **1997**, 99, 174-80	4.5	67
656	Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?. *Blood*, **2006**, 108, 2493-4	2.2	67
655	Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. *European Journal of Haematology*, **2009**, 83, 154-5	3.8	66

654	Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. *American Journal of Hematology*, **2008**, 83, 491-7	7.1	66
653	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. *Leukemia*, **2018**, 32, 1189-1199	10.7	65
652	Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. *American Journal of Hematology*, **2008**, 83, 611-3	7.1	65
651	Clinical, genetic, and therapeutic insights into systemic mast cell disease. *Current Opinion in Hematology*, **2004**, 11, 58-64	3.3	64
650	Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. *American Journal of Hematology*, **2020**, 95, 1599-1613	7.1	64
649	Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. *American Journal of Hematology*, **2011**, 86, 610-1	7.1	61
648	Essential thrombocythemia treatment algorithm 2018. *Blood Cancer Journal*, **2018**, 8, 2	7	60
647	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. *Blood*, **2012**, 120, 569-71	2.2	60
646	Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. *Blood*, **2012**, 119, 5674-7	2.2	59
645	The history of myeloproliferative disorders: before and after Dameshek. *Leukemia*, **2008**, 22, 3-13	10.7	59
644	Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. *Cancer*, **2007**, 109, 2083-8	6.4	59
643	Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. *Blood*, **2001**, 97, 1896	2.2	59
642	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. *British Journal of Haematology*, **2020**, 189, 291-302	4.5	58
641	Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. *American Journal of Hematology*, **2014**, 89, 588-90	7.1	58
640	ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. *American Journal of Hematology*, **2015**, 90, 653-6	7.1	58
639	Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. *Hematology American Society of Hematology Education Program*, **2006**, 2006, 240-5	3.1	58
638	Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome. *Mayo Clinic Proceedings*, **2017**, 92, 1118-1128	6.4	57
637	2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. *British Journal of Haematology*, **1997**, 99, 352-7	4.5	57

636	U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. *Leukemia*, **2014**, 28, 431-3	10.7	56
635	Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. *Blood*, **2011**, 117, 5612-5	2.2	56
634	Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. *Blood*, **2011**, 118, 4595-8	2.2	56
633	The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. *Leukemia*, **2010**, 24, 110-4	10.7	56
632	Long-term outcome of pomalidomide therapy in myelofibrosis. *American Journal of Hematology*, **2012**, 87, 66-8	7.1	55
631	Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. *Blood Cancer Journal*, **2017**, 7, 662	7	55
630	Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. *Bone Marrow Transplantation*, **2006**, 37, 1003-8	4.4	55
629	Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. *Leukemia*, **2001**, 15, 35-40	10.7	55
628	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. *American Journal of Hematology*, **2016**, 91, 492-8	7.1	55
627	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. *Blood Advances*, **2018**, 2, 370-380	7.8	55
626	Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. *American Journal of Hematology*, **2009**, 84, 265-7	7.1	54
625	Anemia after orchiectomy. *American Journal of Hematology*, **1998**, 59, 230-3	7.1	54
624	Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. *American Journal of Hematology*, **2020**, 95, 97-115	7.1	54
623	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. *American Journal of Hematology*, **2018**, 93, 348-355	7.1	54
622	Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. *European Journal of Haematology*, **2009**, 83, 17-21	3.8	53
621	Polycythemia vera: scientific advances and current practice. *Seminars in Hematology*, **2005**, 42, 206-20	4	52
620	Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. *Cancer*, **2005**, 104, 1656-60	6.4	52
619	A bone marrow report of absent stainable iron is not diagnostic of iron deficiency. *Annals of Hematology*, **2001**, 80, 166-9	3	52

618	AKT is a therapeutic target in myeloproliferative neoplasms. *Leukemia*, **2013**, 27, 1882-90	10.7	51
617	Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. *Cancer*, **2009**, 115, 5740-5	6.4	51
616	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Mayo Clinic Proceedings*, **2019**, 94, 599-610	6.4	50
615	Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. *American Journal of Hematology*, **2017**, 92, 1311-1317	7.1	50
614	Essential Thrombocythemia. *New England Journal of Medicine*, **2019**, 381, 2135-2144	59.2	50
613	Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. *Blood*, **2000**, 95, 2226-33	2.2	50
612	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. *Blood Cancer Journal*, **2017**, 7, e584	7	49
611	DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. *American Journal of Hematology*, **2017**, 92, 56-61	7.1	48
610	Polycythemia vera-associated pruritus and its management. *European Journal of Clinical Investigation*, **2010**, 40, 828-34	4.6	48
609	Primer on medical genomics. Part III: Microarray experiments and data analysis. *Mayo Clinic Proceedings*, **2002**, 77, 927-40	6.4	48
608	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. *Leukemia*, **2018**, 32, 2274-2278	10.7	47
607	Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. *Journal of Clinical Investigation*, **2017**, 127, 1316-1320	15.9	47
606	Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. *American Journal of Hematology*, **2016**, 91, 888-93	7.1	47
605	Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. *American Journal of Hematology*, **2016**, 91, 631-42	7.1	47
604	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. *Mayo Clinic Proceedings*, **2005**, 80, 390-402	6.4	46
603	Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. *American Journal of Hematology*, **2021**, 96, 145-162	7.1	46
602	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. *American Journal of Hematology*, **2015**, 90, 411-6	7.1	45
601	Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. *Leukemia*, **2013**, 27, 1617-20	10.7	44

600	Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. *Cancer*, **2011**, 117, 4869-4877	6.4	44
599	Polycythemia vera treatment algorithm 2018. *Blood Cancer Journal*, **2018**, 8, 3	7	43
598	Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. *Leukemia*, **2012**, 26, 2439-41	10.7	43
597	The forgotten myeloproliferative disorder: myeloid metaplasia. *Oncologist*, **2003**, 8, 225-31	5.7	43
596	Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. *Clinical Cancer Research*, **2019**, 25, 4898-4906	12.9	42
595	Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. *Leukemia*, **2014**, 28, 1363-5	10.7	42
594	JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. *Blood Reviews*, **2011**, 25, 229-37	11.1	42
593	Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. *American Journal of Hematology*, **2011**, 86, 1017-26	7.1	42
592	Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. *American Journal of Hematology*, **2017**, 92, 542-548	7.1	41
591	Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. *European Journal of Haematology*, **2000**, 65, 170-4	3.8	41
590	Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 215-37	5.6	40
589	Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion. *American Journal of Hematology*, **1994**, 45, 187-8	7.1	40
588	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. *Leukemia*, **2020**, 34, 1407-1421	10.7	40
587	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. *Blood Advances*, **2018**, 2, 2964-2972	7.8	40
586	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2017**, 92, 297-310	7.1	39
585	Abdominal vein thrombosis in essential thrombocythemia: prevalence, clinical correlates, and prognostic implications. *European Journal of Haematology*, **2006**, 77, 327-33	3.8	39
584	Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. *Blood*, **2004**, 103, 3547-8	2.2	39
583	Modern diagnosis and treatment of primary eosinophilia. *Acta Haematologica*, **2005**, 114, 52-60	2.7	39

582	Rethinking the diagnostic criteria of polycythemia vera. *Leukemia*, **2014**, 28, 1191-5	10.7	38
581	Atypical myeloproliferative disorders: diagnosis and management. *Mayo Clinic Proceedings*, **2006**, 81, 553-63	6.4	38
580	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. *American Journal of Hematology*, **2018**, 93, 65-73	7.1	37
579	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. *American Journal of Hematology*, **2016**, 91, 503-6	7.1	37
578	Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count. *American Journal of Hematology*, **2010**, 85, 545	7.1	36
577	JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications. *New England Journal of Medicine*, **2007**, 356, 444-5	59.2	36
576	bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. *Mayo Clinic Proceedings*, **2005**, 80, 1220-32	6.4	36
575	Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. *Blood*, **2001**, 97, 3665-7	2.2	36
574	Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. *British Journal of Haematology*, **1999**, 106, 682-8	4.5	36
573	Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. *Journal of Clinical Oncology*, **1994**, 12, 569-74	2.2	36
572	Primary thrombocythemia. *Seminars in Oncology*, **1995**, 22, 334-40	5.5	36
571	Myeloproliferative neoplasms: Morphology and clinical practice. *American Journal of Hematology*, **2016**, 91, 430-3	7.1	36
570	Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. *European Journal of Haematology*, **2015**, 94, 31-6	3.8	35
569	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. *Leukemia*, **2018**, 32, 1035-1038	10.7	35
568	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. *Leukemia and Lymphoma*, **2017**, 58, 1488-1493	1.9	35
567	A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. *Leukemia*, **2017**, 31, 896-902	10.7	35
566	Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2015**, 5, e275	7	35
565	Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. *American Journal of Clinical Pathology*, **1996**, 106, 457-61	1.9	35

564	Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. *American Journal of Hematology*, **2018**, 93, E47-E49	7.1	35
563	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. *American Journal of Hematology*, **2018**, 93, 691-697	7.1	34
562	Genetic Risk Assessment in Myeloproliferative Neoplasms. *Mayo Clinic Proceedings*, **2017**, 92, 1283-1290	6.4	34
561	Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. *American Journal of Clinical Pathology*, **2000**, 113, 212-8	1.9	34
560	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. *Leukemia*, **2015**, 29, 741-4	10.7	33
559	Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). *Leukemia*, **2015**, 29, 20-6	10.7	33
558	Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2011**, 86, 292-301	7.1	33
557	Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. *Mayo Clinic Proceedings*, **2015**, 90, 1283-93	6.4	32
556	Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. *Blood Cancer Journal*, **2016**, 6, e472	7	32
555	The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. *American Journal of Hematology*, **2017**, 92, E5-E6	7.1	32
554	New drugs in essential thrombocythemia and polycythemia vera. *Blood Reviews*, **1997**, 11, 1-7	11.1	32
553	Paraneoplastic cholestasis and hypercoagulability associated with medullary thyroid carcinoma. Resolution with tumor debulking. *Cancer*, **1994**, 73, 702-5	6.4	32
552	Monocytosis in polycythemia vera: Clinical and molecular correlates. *American Journal of Hematology*, **2017**, 92, 640-645	7.1	31
551	Refractory anemia with ring sideroblasts and RARS with thrombocytosis. *American Journal of Hematology*, **2015**, 90, 549-59	7.1	31
550	Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility. *Cancer*, **2005**, 104, 213-5	6.4	31
549	Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. *British Journal of Haematology*, **1996**, 93, 406-8	4.5	31
548	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. *American Journal of Hematology*, **2018**, 93, 1474-1484	7.1	31
547	Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience. *American Journal of Hematology*, **2018**, 93, E123-E125	7.1	30

546	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. *Blood Cancer Journal*, **2018**, 8, 12	7	30
545	How I treat myelofibrosis after failure of JAK inhibitors. *Blood*, **2018**, 132, 492-500	2.2	30
544	Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. *American Journal of Hematology*, **2010**, 85, 14-7	7.1	30
543	Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. *Best Practice and Research in Clinical Haematology*, **2006**, 19, 365-85	4.2	30
542	Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. *Blood*, **2000**, 96, 3644-3646	2.2	30
541	Agnogenic myeloid metaplasia. *Seminars in Oncology*, **1995**, 22, 327-33	5.5	30
540	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. *Blood*, **2013**, 122, 108-108	2.2	30
539	Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. *Leukemia*, **2016**, 30, 1924-6	10.7	30
538	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. *American Journal of Hematology*, **2013**, 88, 690-3	7.1	29
537	Mutation screening for JAK2V617F: when to order the test and how to interpret the results. *Leukemia Research*, **2006**, 30, 739-44	2.7	29
536	Concurrent inflammatory bowel disease and myelodysplastic syndromes. *Inflammatory Bowel Diseases*, **1999**, 5, 98-103	4.5	29
535	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. *Blood Cancer Journal*, **2019**, 9, 12	7	28
534	Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: a case report. *American Journal of Hematology*, **1997**, 55, 148-55	7.1	28
533	Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. *Blood*, **2020**, 136, 909-913	2.2	28
532	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. *American Journal of Hematology*, **2020**, 95, 1511-1521	7.1	28
531	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. *American Journal of Hematology*, **2019**, 94, 767-779	7.1	27
530	Momelotinib therapy for myelofibrosis: a 7-year follow-up. *Blood Cancer Journal*, **2018**, 8, 29	7	27
529	Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. *American Journal of Hematology*, **2009**, 84, 629-30	7.1	27

528	20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. *European Journal of Haematology*, **2008**, 80, 386-90	3.8	27
527	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. *American Journal of Hematology*, **2020**, 95, 156-166	7.1	27
526	Systemic mastocytosis: current concepts and treatment advances. *Psychophysiology*, **2004**, 3, 197-202		27
525	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. *Leukemia*, **2018**, 32, 1254-1258	10.7	26
524	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. *American Journal of Hematology*, **2018**, 93, 649-654	7.1	26
523	CALR mutation studies in chronic neutrophilic leukemia. *American Journal of Hematology*, **2014**, 89, 450	7.1	26
522	JAK2 mutations and clinical practice in myeloproliferative neoplasms. *Cancer Journal (Sudbury, Mass)*, **2007**, 13, 366-71	2.2	26
521	Chronic natural killer cell lymphocytosis: a descriptive clinical study. *Blood*, **1994**, 84, 2721-5	2.2	26
520	Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience. *American Journal of Hematology*, **2018**, 93, 1029	7.1	26
519	Aberrant expression of CD123 (interleukin-3 receptor-□) on neoplastic mast cells. *Leukemia*, **2015**, 29, 1605-8	10.7	25
518	Definition and management of ruxolitinib treatment failure in myelofibrosis. *Blood Cancer Journal*, **2014**, 4, e268	7	25
517	Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. *Mayo Clinic Proceedings*, **2007**, 82, 599-604	6.4	25
516	The diagnostic interface between histology and molecular tests in myeloproliferative disorders. *Current Opinion in Hematology*, **2007**, 14, 115-22	3.3	25
515	Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. *Leukemia Research*, **2003**, 27, 775-82	2.7	25
514	Primer on medical genomics part II: Background principles and methods in molecular genetics. *Mayo Clinic Proceedings*, **2002**, 77, 785-808	6.4	25
513	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. *Blood Cancer Journal*, **2016**, 6, e405	7	24
512	Chronic natural killer cell lymphocytosis. *Leukemia and Lymphoma*, **1996**, 20, 245-8	1.9	24
511	Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. *American Journal of Hematology*, **2008**, 83, 708-13	7.1	24

510	ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. *Blood Cancer Journal*, **2015**, 5, e315	7	23
509	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. *British Journal of Haematology*, **2018**, 183, 835-838	4.5	23
508	CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value. *Leukemia*, **2016**, 30, 914-8	10.7	23
507	Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin's disease. *Journal of Clinical Oncology*, **1990**, 8, 1959-65	2.2	23
506	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". *American Journal of Hematology*, **2019**, 94, 475-488	7.1	23
505	Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. *American Journal of Hematology*, **2018**, 93, E61-E64	7.1	23
504	Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients. *Blood Cancer Journal*, **2018**, 8, 119	7	23
503	Myelofibrosis Treatment Algorithm 2018. *Blood Cancer Journal*, **2018**, 8, 72	7	22
502	Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. *American Journal of Clinical Pathology*, **2010**, 133, 942-8	1.9	22
501	Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. *European Journal of Haematology*, **2010**, 85, 192-9	3.8	22
500	Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. *Leukemia and Lymphoma*, **1994**, 14, 137-9	1.9	22
499	Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. *American Journal of Hematology*, **1994**, 46, 325-8	7.1	22
498	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. *Blood Cancer Journal*, **2015**, 5, e270	7	21
497	Myelofibrosis biology and contemporary management. *British Journal of Haematology*, **2020**, 191, 152-170	4.5	21
496	MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. *Leukemia*, **2010**, 24, 859-60	10.7	21
495	Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. *Leukemia*, **2018**, 32, 837-839	10.7	20
494	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. *American Journal of Hematology*, **2017**, 92, E614-E618	7.1	20
493	Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. *Cancer*, **2006**, 106, 2406-11	6.4	20

492	Essential thrombocythemia: scientific advances and current practice. *Current Opinion in Hematology*, **2006**, 13, 93-8	3.3	20
491	A critical review of anagrelide therapy in essential thrombocythemia and related disorders. *Leukemia and Lymphoma*, **2005**, 46, 641-50	1.9	20
490	Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. *American Journal of Hematology*, **2018**, 93, 578-587	7.1	19
489	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. *Leukemia*, **2018**, 32, 1850-1856	10.7	19
488	MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. *Blood Cancer Journal*, **2016**, 6, e487	7	19
487	Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. *Mayo Clinic Proceedings*, **2016**, 91, 259-72	6.4	19
486	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. *Leukemia*, **2018**, 32, 2512-2518	10.7	19
485	Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. *American Journal of Hematology*, **2010**, 85, 160-3	7.1	19
484	Palliative splenectomy in myelofibrosis with myeloid metaplasia. *Leukemia and Lymphoma*, **2001**, 42, 901-11	1.9	19
483	ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. *British Journal of Haematology*, **2016**, 175, 534-536	4.5	19
482	Diagnostic impact of the 2016 revised who criteria for polycythemia vera. *American Journal of Hematology*, **2017**, 92, 417-419	7.1	18
481	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. *British Journal of Haematology*, **2018**, 182, 594-597	4.5	18
480	Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. *American Journal of Hematology*, **2017**, 92, 1193-1197	7.1	18
479	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. *Leukemia and Lymphoma*, **2017**, 58, 872-881	1.9	18
478	Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. *Cancer*, **2006**, 106, 1739-43	6.4	18
477	Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. *Leukemia and Lymphoma*, **2006**, 47, 2055-61	1.9	18
476	New insights into the pathogenesis and drug treatment of myelofibrosis. *Current Opinion in Hematology*, **2006**, 13, 87-92	3.3	18
475	Demonstration of clonality, by X-linked DNA analysis, in chronic natural killer cell lymphocytosis and successful therapy with oral cyclophosphamide. *Leukemia*, **1992**, 6, 477-80	10.7	18

474	Mutations and karyotype predict treatment response in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, 1420-1426	7.1	18
473	Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis. *American Journal of Hematology*, **2016**, 91, E12-4	7.1	17
472	Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. *Blood Cancer Journal*, **2018**, 8, 57	7	17
471	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. *Blood Cancer Journal*, **2018**, 8, 21	7	17
470	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. *American Journal of Hematology*, **2018**, 93, 1461-1466	7.1	17
469	Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. *American Journal of Hematology*, **2017**, 92, 1187-1192	7.1	17
468	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. *Blood*, **2019**, 134, 558-558	2.2	17
467	INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. *Blood*, **2007**, 110, 558-558	2.2	17
466	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. *Blood Advances*, **2020**, 4, 3677-3687	7.8	17
465	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. *American Journal of Hematology*, **2021**, 96, 781-789	7.1	17
464	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation. *American Journal of Hematology*, **2016**, 91, E10-1	7.1	17
463	Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management. *American Journal of Hematology*, **2016**, 91, 341-9	7.1	17
462	Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. *Blood Cancer Journal*, **2017**, 7, e538	7	16
461	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. *Blood Cancer Journal*, **2016**, 6, e414	7	16
460	Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. *Leukemia*, **2017**, 31, 2851-2852	10.7	16
459	Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. *Journal of Molecular Diagnostics*, **2011**, 13, 461-6	5.1	16
458	Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. *American Journal of Hematology*, **2010**, 85, 808-10	7.1	16
457	Is Hydroxyurea Leukemogenic in Essential Thrombocythemia?. *Blood*, **1998**, 92, 1459-1461	2.2	16

456	The 5q- syndrome: a scientific and clinical update. *Leukemia and Lymphoma*, **1994**, 14, 375-8	1.9	16
455	Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. *Leukemia*, **2016**, 30, 2273-2275	10.7	16
454	Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. *Current Opinion in Hematology*, **2015**, 22, 171-6	3.3	15
453	Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review. *Journal of Oncology Practice*, **2016**, 12, 611-21	3.1	15
452	Clinical and laboratory characteristics in congenital ANKRD26 mutation-associated thrombocytopenia: A detailed phenotypic study of a family. *Platelets*, **2016**, 27, 712-715	3.6	15
451	Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2001**, 28, 997-9	4.4	15
450	Correlation of clinical outcome with the degree of surface immunoglobulin (sIg) expression in B-cell chronic lymphocytic leukemia. *American Journal of Clinical Pathology*, **1989**, 92, 82-5	1.9	15
449	BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis. *Blood*, **2013**, 122, 664-664	2.2	15
448	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. *Blood Cancer Journal*, **2017**, 7, e550	7	14
447	Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. *Leukemia*, **2015**, 29, 498-500	10.7	14
446	JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. *American Journal of Hematology*, **2018**, 93, E93-E96	7.1	14
445	Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. *British Journal of Haematology*, **2018**, 182, 437-440	4.5	14
444	Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). *American Journal of Hematology*, **2018**, 93, E27-E30	7.1	14
443	Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience. *Blood Cancer Journal*, **2016**, 6, e427	7	14
442	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. *Mayo Clinic Proceedings*, **2018**, 93, 1363-1374	6.4	14
441	Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. *American Journal of Clinical Pathology*, **2016**, 146, 86-94	1.9	14
440	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. *Blood Cancer Journal*, **2018**, 8, 82	7	14
439	New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. *American Journal of Hematology*, **2015**, 90, 683-5	7.1	13

438	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. *Blood Cancer Journal*, **2018**, 8, 18	7	13
437	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). *Blood Cancer Journal*, **2017**, 7, 658	7	13
436	Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. *Leukemia Research*, **2012**, 36, 1481-9	2.7	13
435	Suramin toxicity and efficacy in agnogenic myeloid metaplasia. *Journal of the National Cancer Institute*, **1993**, 85, 1520-2	9.7	13
434	Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. *Blood*, **1990**, 75, 1770-3	2.2	13
433	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. *Blood*, **2013**, 122, 394-394	2.2	13
432	Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients. *British Journal of Haematology*, **2020**, 191, e120-e124	4.5	13
431	Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the V617F mutation. *Haematologica*, **2019**, 104, e236-e239	6.6	13
430	MPL-mutated essential thrombocythemia: a morphologic reappraisal. *Blood Cancer Journal*, **2018**, 8, 121	7	13
429	JAK2 in myeloproliferative disorders is not just another kinase. *Cell Cycle*, **2005**, 4, 1053-6	4.7	13
428	WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic. *American Journal of Hematology*, **2020**, 95, E172-E174	7.1	12
427	Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2019**, 9, 65	7	12
426	Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. *International Journal of Hematology*, **2004**, 79, 441-7	2.3	12
425	Adult-onset cyclic bicytopenia: a case report and review of treatment of cyclic hematopoiesis. *American Journal of Hematology*, **1989**, 30, 181-5	7.1	12
424	Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management. *American Journal of Hematology*, **2020**, 95, 212-224	7.1	12
423	A contemporary approach to the diagnosis and management of polycythemia vera. *Psychophysiology*, **2003**, 2, 237-41		12
422	The rise and fall of red cell mass measurement in polycythemia vera. *Psychophysiology*, **2005**, 4, 213-7		12
421	The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis. *Leukemia*, **2015**, 29, 992-3	10.7	11

420	Chronic neutrophilic leukemia: new science and new diagnostic criteria. *Blood Cancer Journal*, **2018**, 8, 19	7	11
419	Mayo CALR mutation type classification guide using alpha helix propensity. *American Journal of Hematology*, **2018**, 93, E128-E129	7.1	11
418	Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. *Leukemia*, **2014**, 28, 2092-4	10.7	11
417	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. *American Journal of Hematology*, **2015**, 90, 434-7	7.1	11
416	Myelodysplastic syndromes--many new drugs, little therapeutic progress. *Mayo Clinic Proceedings*, **2010**, 85, 1042-5	6.4	11
415	Current perspective in agnogenic myeloid metaplasia. *Leukemia and Lymphoma*, **1996**, 22 Suppl 1, 169-71	1.9	11
414	Concurrent activating KIT mutations in systemic mastocytosis. *British Journal of Haematology*, **2016**, 173, 153-6	4.5	11
413	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. *Blood Cancer Journal*, **2021**, 11, 49	7	11
412	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. *Mayo Clinic Proceedings*, **2015**, 90, 1623-38	6.4	10
411	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. *Leukemia*, **2020**, 34, 2519-2524	10.7	10
410	CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. *Leukemia*, **2014**, 28, 1370-1	10.7	10
409	Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain. *American Journal of Hematology*, **2010**, 85, 93-4	7.1	10
408	The diagnosis of polycythemia vera: new tests and old dictums. *Best Practice and Research in Clinical Haematology*, **2006**, 19, 455-69	4.2	10
407	Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424. *Blood*, **2008**, 112, 2802-2802	2.2	10
406	A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis. *Blood*, **2010**, 116, 630-630	2.2	10
405	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. *Blood*, **2011**, 118, 3849-3849	2.2	10
404	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. *Blood*, **2013**, 122, 662-662	2.2	10
403	Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. *Annals of Hematology*, **2016**, 95, 1185-9	3	10

402	Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis. *American Journal of Hematology*, **2019**, 94, E1-E2	7.1	10
401	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. *British Journal of Haematology*, **2018**, 183, 678-681	4.5	10
400	Concurrent inflammatory bowel disease and myelodysplastic syndromes. *Inflammatory Bowel Diseases*,5, 98-103	4.5	10
399	The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. *American Journal of Hematology*, **2017**, 92, 454-459	7.1	9
398	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. *Blood Cancer Journal*, **2018**, 8, 32	7	9
397	Acute leukemia in pregnancy: a single institution experience with 23 patients. *Leukemia and Lymphoma*, **2017**, 58, 1052-1060	1.9	9
396	Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. *Journal of the American Academy of Dermatology*, **2011**, 65, 673-674	4.5	9
395	Iron chelation therapy for myelodysplastic syndrome: if and when. *Mayo Clinic Proceedings*, **2006**, 81, 197-8	6.4	9
394	Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates. *Leukemia Research*, **2006**, 30, 677-80	2.7	9
393	Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new. *Seminars in Hematology*, **2003**, 40, 18-21	4	9
392	The pathogenesis of chronic myeloproliferative diseases. *International Journal of Hematology*, **2001** , 73, 170-6	2.3	9
391	Secondary T-cell lymphoma in the setting of nodular lymphocyte predominance Hodgkin's disease. *American Journal of Hematology*, **1992**, 40, 232-3	7.1	9
390	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2018**, 132, 1821-1821	2.2	9
389	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. *Blood* , **2015**, 126, 354-354	2.2	9
388	Primary myelofibrosis. *Cancer Treatment and Research*, **2008**, 142, 29-49	3.5	9
387	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. *Blood Cancer Journal*, **2019**, 9, 11	7	8
386	Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. *Blood Advances*, **2018**, 2, 1980-1984	7.8	8
385	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. *Mayo Clinic Proceedings*, **2019**, 94, 1467-1474	6.4	8

384	Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. *Leukemia and Lymphoma*, **2010**, 51, 576-82	1.9	8
383	Bone marrow granulomas associated with chronic natural killer cell lymphocytosis. *American Journal of Hematology*, **1997**, 54, 258-62	7.1	8
382	Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.. *Blood*, **2007**, 110, 3543-3543	2.2	8
381	SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis,. *Blood*, **2011**, 118, 3838-3838	2.2	8
380	Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. *Blood Cancer Journal*, **2020**, 10, 122	7	8
379	Mutations and thrombosis in essential thrombocythemia. *Blood Cancer Journal*, **2021**, 11, 77	7	8
378	Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. *Blood Cancer Journal*, **2016**, 6, e415	7	8
377	Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management". *American Journal of Hematology*, **2021**, 96, 379-394	7.1	8
376	Polycythemia vera and essential thrombocythemia: algorithmic approach. *Current Opinion in Hematology*, **2018**, 25, 112-119	3.3	8
375	Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. *Blood*, **2000**, 96, 771-2	2.2	8
374	A population-based study of chronic neutrophilic leukemia in the United States. *Blood Cancer Journal*, **2020**, 10, 68	7	7
373	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. *American Journal of Hematology*, **2020**, 95, E203-E208	7.1	7
372	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. *American Journal of Hematology*, **2018**, 93, E146-E148	7.1	7
371	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. *American Journal of Hematology*, **2018**, 93, E235-E238	7.1	7
370	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. *American Journal of Hematology*, **2018**, 93, 1347-1357	7.1	7
369	Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia. *Hematological Oncology*, **2018**, 36, 718-720	1.3	7
368	Current management of polycythemia vera. *Leukemia and Lymphoma*, **2002**, 43, 1-7	1.9	7
367	Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis. *Blood*, **2018**, 132, 688-688	2.2	7

366	Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. *Blood*, **2012**, 120, 178-178	2.2	7
365	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2020**, 10, 121	7	7
364	JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. *Leukemia*, **2021**, 35, 2166-2181	10.7	7
363	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. *British Journal of Haematology*, **2021**, 195, 244-248	4.5	7
362	Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. *Hematological Oncology*, **2019**, 37, 96-102	1.3	7
361	Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. *Leukemia*, **2021**, 35, 3339-3351	10.7	7
360	Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976–1995 **1999**, 61, 10		7
359	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. *Blood Cancer Journal*, **2020**, 10, 36	7	6
358	The new WHO classification for essential thrombocythemia calls for revision of available evidences. *Blood Cancer Journal*, **2020**, 10, 22	7	6
357	Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies. *American Journal of Hematology*, **2020**, 95, E114-E117	7.1	6
356	JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.. *Blood Cancer Journal*, **2021**, 11, 199	7	6
355	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. *Blood*, **2020**, 136, 39-40	2.2	6
354	A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.. *Blood*, **2012**, 120, 2837-2837	2.2	6
353	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. *Blood*, **2013**, 122, 4067-4067	2.2	6
352	Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. *American Journal of Hematology*, **2021**, 96, E182-E184	7.1	6
351	Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience. *American Journal of Hematology*, **2016**, 91, E296-7	7.1	6
350	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. *Modern Pathology*, **2020**, 33, 334-343	9.8	6
349	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. *Leukemia*, **2021**, 35, 644-649	10.7	6

348	World Health Organization class-independent risk categorization in mastocytosis. *Blood Cancer Journal*, **2019**, 9, 29	7	5
347	FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous. *Leukemia and Lymphoma*, **2018**, 59, 1520-1522	1.9	5
346	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. *Leukemia and Lymphoma*, **2018**, 59, 2998-3001	1.9	5
345	Etiologies of Extreme Thrombocytosis: A Contemporary Series. *Mayo Clinic Proceedings*, **2019**, 94, 1542-1550	6.4	5
344	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. *Blood Cancer Journal*, **2017**, 7, 657	7	5
343	Genomics basics: DNA structure, gene expression, cloning, genetic mapping, and molecular tests. *Seminars in Cardiothoracic and Vascular Anesthesia*, **2006**, 10, 282-90	1.4	5
342	Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review. *Leukemia and Lymphoma*, **2001**, 42, 1243-53	1.9	5
341	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). *Blood*, **2018**, 132, 578-578	2.2	5
340	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. *Blood Advances*, **2020**, 4, 5716-5721	7.8	5
339	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. *American Journal of Hematology*, **2019**, 94, 299-305	7.1	5
338	Young platelet millionaires with essential thrombocythemia. *American Journal of Hematology*, **2021**, 96, E93-E95	7.1	5
337	Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. *American Journal of Hematology*, **2019**, 94, E231-E234	7.1	4
336	Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. *Blood Cancer Journal*, **2015**, 5, e286	7	4
335	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). *British Journal of Haematology*, **2020**, 189, e104-e108	4.5	4
334	Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. *British Journal of Haematology*, **2020**, 190, e316-e320	4.5	4
333	Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. *Blood Cancer Journal*, **2016**, 6, e436	7	4
332	The indolent natural history of essential thrombocythemia: a challenge to new drug development. *Mayo Clinic Proceedings*, **2005**, 80, 97-8	6.4	4
331	Introduction to a cancer symposium for the practitioner. *Mayo Clinic Proceedings*, **2005**, 80, 1085-6	6.4	4

330	Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha. *American Journal of Hematology*, **1996**, 52, 231-3	7.1	4
329	Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.. *American Journal of Hematology*, **2022**,	7.1	4
328	Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.. *Blood*, **2006**, 108, 300-300	2.2	4
327	Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms. *Blood*, **2010**, 116, 3070-3070	2.2	4
326	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. *Blood*, **2011**, 118, 277-277	2.2	4
325	The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. *Blood*, **2011**, 118, 3839-3839	2.2	4
324	Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. *Blood*, **2012**, 120, 2851-2851	2.2	4
323	Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). *Blood*, **2013**, 122, 4047-4047	2.2	4
322	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. *Blood*, **2016**, 128, 1123-1123	2.2	4
321	Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. *American Journal of Hematology*, **2021**, 96, 354-366	7.1	4
320	Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies. *American Journal of Hematology*, **2020**, 95, 1224	7.1	3
319	AKT activation is a feature of CALR mutant myeloproliferative neoplasms. *Leukemia*, **2019**, 33, 271-274	10.7	3
318	Acquired factor V deficiency in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients. *British Journal of Haematology*, **2015**, 171, 875-9	4.5	3
317	Myeloproliferative neoplasms: thrombophilic clonal stem cell diseases. *Cancer Treatment and Research*, **2009**, 148, 157-79	3.5	3
316	Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?. *Leukemia and Lymphoma*, **2006**, 47, 1724-5	1.9	3
315	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. *Blood*, **2018**, 132, 1773-1773	2.2	3
314	A Phase II Study of CC-5013 Treatment for Myelofibrosis with Myeloid Metaplasia: A Preliminary Report.. *Blood*, **2004**, 104, 1505-1505	2.2	3
313	TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.. *Blood*, **2006**, 108, 2680-2680	2.2	3

312	Dasatinib (Sprycel) Therapy for Patients with Systemic Mastocytosis.. *Blood*, **2006**, 108, 3627-3627	2.2	3
311	Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. *Blood*, **2012**, 120, 424-424	2.2	3
310	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. *Blood*, **2013**, 122, 104-104	2.2	3
309	Real-World Myelodysplastic Syndrome-unclassifiable and Its Comparison With Refractory Cytopenia With Multi-Lineage dysplasia and Refractory anemia *Blood*, **2013**, 122, 1574-1574	2.2	3
308	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. *Blood*, **2015**, 126, 55-55	2.2	3
307	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. *Blood*, **2016**, 128, 2798-2798	2.2	3
306	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. *Blood*, **2016**, 128, 3604-3604	2.2	3
305	Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. *Blood*, **2000**, 96, 3644-3646	2.2	3
304	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. *British Journal of Haematology*, **2021**,	4.5	3
303	High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. *American Journal of Hematology*, **2021**, 96, 1647-1654	7.1	3
302	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. *Blood Cancer Journal*, **2020**, 10, 100	7	3
301	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA venetoclax chemotherapy. *American Journal of Hematology*, **2021**, 96, E108-E111	7.1	3
300	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. *Blood Cancer Journal*, **2021**, 11, 43	7	3
299	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. *Blood Advances*, **2021**, 5, 2272-2278	7.8	3
298	The prognostic impact of bone marrow fibrosis in primary myelofibrosis. *American Journal of Hematology*, **2016**, 91, E454	7.1	3
297	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. *American Journal of Hematology*, **2019**, 94, 286-290	7.1	3
296	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. *American Journal of Hematology*, **2019**, 94, 5-9	7.1	3
295	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. *Blood Cancer Journal*, **2018**, 8, 118	7	3

294	Natural leukocyte interferon-□ therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-□ **1996**, 52, 231		3
293	Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach.. *American Journal of Hematology*, **2022**,	7.1	3
292	The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. *British Journal of Haematology*, **2017**, 178, 57-60	4.5	2
291	Cardiac tamponade in myelofibrosis: A Mayo clinic series of nine consecutive cases. *American Journal of Hematology*, **2017**, 92, E544-E545	7.1	2
290	Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. *European Journal of Haematology*, **2017**, 99, 36-41	3.8	2
289	Comments on pre-fibrotic myelofibrosis and how should it be managed. *British Journal of Haematology*, **2019**, 186, 358-360	4.5	2
288	MPN-377: Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, S338-S339	2	2
287	A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. *American Journal of Hematology*, **2020**, 95, E257	7.1	2
286	Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. *American Journal of Hematology*, **2020**, 95, E86-E89	7.1	2
285	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. *British Journal of Haematology*, **2018**, 182, 141-145	4.5	2
284	Targeted therapy in KITD816V-positive mastocytosis: waiting for proof-of-principle. *Leukemia and Lymphoma*, **2010**, 51, 360-2	1.9	2
283	Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. *Leukemia and Lymphoma*, **2008**, 49, 2231-2	1.9	2
282	Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?. *Leukemia and Lymphoma*, **2008**, 49, 1225-7	1.9	2
281	Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed. *Blood*, **2001**, 97, 3321-2	2.2	2
280	Myelodysplastic syndrome and pregnancy: the Mayo Clinic experience. *Leukemia and Lymphoma*, **2001**, 42, 1229-34	1.9	2
279	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. *American Journal of Hematology*, **2021**,	7.1	2
278	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.. *Blood Cancer Journal*, **2022**, 12, 28	7	2
277	Direct Oral Anticoagulants in Patients with Myeloproliferative Neoplasms: A Single Institution Retrospective Study. *Blood*, **2018**, 132, 5067-5067	2.2	2

276	Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms. *Blood*, **2020**, 136, 1-1	2.2	2
275	Red Cell Mass Measurement in Polycythemia: Evaluation of Performance and Added Value.. *Blood*, **2004**, 104, 1525-1525	2.2	2
274	The Increasing Relevance of Copper Deficiency in Hematological Practice.. *Blood*, **2005**, 106, 1679-1679	2.2	2
273	Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.. *Blood*, **2007**, 110, 3546-3546	2.2	2
272	Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. *Blood*, **2010**, 116, 4112-4112	2.2	2
271	Induction of Megakaryocyte Polyploidization in Combination with JAK Inhibition As a Novel Therapeutic Strategy for Myeloproliferative Neoplasms. *Blood*, **2011**, 118, 64-64	2.2	2
270	Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis.. *Blood*, **2012**, 120, 2867-2867	2.2	2
269	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. *Blood*, **2013**, 122, 1510-1510	2.2	2
268	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. *Blood*, **2015**, 126, 828-828	2.2	2
267	Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. *Blood*, **2016**, 128, 3113-3113	2.2	2
266	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. *Blood*, **2016**, 128, 4247-4247	2.2	2
265	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. *Blood*, **2016**, 128, 4249-4249	2.2	2
264	Chronic natural killer cell lymphocytosis: a descriptive clinical study. *Blood*, **1994**, 84, 2721-2725	2.2	2
263	A JAK2V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis. *Blood*, **2021**, 138, 237-237	2.2	2
262	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. *Blood*, **2021**, 138, 219-219	2.2	2
261	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. *American Journal of Hematology*, **2021**, 97, E35	7.1	2
260	Early Peripheral Blood Blast Clearance during Induction Chemotherapy for Acute Myeloid Leukemia (AML) Predicts Superior Relapse-Free Survival.. *Blood*, **2007**, 110, 1848-1848	2.2	2
259	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **2018**, 132, 2722-2722	2.2	2

258	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. *American Journal of Hematology*, **2020**, 95, E68-E72	7.1	2
257	New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat. *American Journal of Hematology*, **2021**, 96, 761-763	7.1	2
256	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, E327-E330	7.1	2
255	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. *Leukemia*, **2019**, 33, 780-785	10.7	2
254	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. *Blood and Lymphatic Cancer: Targets and Therapy*, **2021**, 11, 1-9	2.6	2
253	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. *American Journal of Hematology*, **2018**, 93, E401-E404	7.1	2
252	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. *American Journal of Hematology*, **2018**, 93, E383-E386	7.1	2
251	Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms. *American Journal of Hematology*, **2021**, 96, E392-E396	7.1	2
250	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. *American Journal of Hematology*, **2021**, 96, 1472-1480	7.1	2
249	Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. *American Journal of Hematology*, **2021**, 96, E433-E436	7.1	2
248	Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. *American Journal of Hematology*, **2021**, 96, 1580-1586	7.1	2
247	Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review **1998**, 59, 161		2
246	Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. *Blood*, **2000**, 96, 1582-4	2.2	2
245	Schistocytes on the peripheral blood smear. *Mayo Clinic Proceedings*, **2004**, 79, 809	6.4	2
244	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.. *American Journal of Hematology*, **2022**,	7.1	2
243	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. *British Journal of Haematology*,	4.5	2
242	Liver function test abnormalities and their clinical relevance in primary myelofibrosis. *Blood Cancer Journal*, **2017**, 7, e557	7	1
241	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. *Leukemia*, **2019**, 33, 2522-2553	10.7	1

240	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, E164-E167	7.1	1
239	Revisiting the need for bone marrow examination in chronic myeloid leukemia. *American Journal of Hematology*, **2018**, 93, 5-7	7.1	1
238	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. *Clinical Genitourinary Cancer*, **2018**, 16, e1117-e1122	3.3	1
237	Blast-phase chronic myelomonocytic leukemia: more than just semantics. *Leukemia*, **2018**, 32, 2093-2094	10.7	1
236	Altered expression of tumor suppressor PHF20 in myeloproliferative neoplasms. *Leukemia*, **2014**, 28, 1762-4	10.7	1
235	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. *American Journal of Hematology*, **2017**, 92, E626-E627	7.1	1
234	Pregnancy and thrombocythemia. *American Journal of Hematology*, **1998**, 57, 181-2	7.1	1
233	Suppressors of cytokine signaling and regulation of clonal erythropoiesis. *Leukemia and Lymphoma*, **2007**, 48, 7-8	1.9	1
232	The spleen in myelofibrosis with myeloid metaplasia. *Mayo Clinic Proceedings*, **2004**, 79, 503	6.4	1
231	Primer on medical genomics. The end of the beginning. *Mayo Clinic Proceedings*, **2004**, 79, 659-60	6.4	1
230	Fever of unknown origin associated with chronic natural killer cell lymphocytosis. *American Journal of Hematology*, **1996**, 53, 56	7.1	1
229	Efficacy of Venetoclax Plus Hypomethylating Agent in Blast Phase Myeloproliferative Neoplasm. *Blood*, **2020**, 136, 21-21	2.2	1
228	A Population-Based Study of Acute Panmyelosis with Myelofibrosis in the United States: 2004-2015.. *American Journal of Hematology*, **2022**,	7.1	1
227	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.. *Blood Cancer Journal*, **2022**, 12, 7	7	1
226	Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.. *American Journal of Hematology*, **2022**,	7.1	1
225	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. *Blood Cancer Journal*, **2022**, 12, 26	7	1
224	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. *Haematologica*, **2022**,	6.6	1
223	Erythrocytosis associated with (), (), or mutations: The Mayo Clinic experience.. *Haematologica*, **2022**,	6.6	1

222	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Blood*, **2018**, 132, 3035-3035	2.2	1
221	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. *Blood*, **2018**, 132, 3040-3040	2.2	1
220	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. *Blood*, **2019**, 134, 3003-3003	2.2	1
219	Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma.. *Blood*, **2004**, 104, 2927-2927	2.2	1
218	Blood CD34 Count in Myelofibrosis with Myeloid Metaplasia: A Prospective Evaluation of Prognostic Value in 94 Patients.. *Blood*, **2004**, 104, 662-662	2.2	1
217	Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.. *Blood*, **2004**, 104, 892-892	2.2	1
216	The Role of Stem Cell Mobilization Regimen on Lymphocyte Collection Yield and Survival after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.. *Blood*, **2005**, 106, 1174-1174	2.2	1
215	Neither Serum Ferritin Nor Number of Red Blood Cell Transfusions Affect Overall Survival in Refractory Anemia with Ringed Sideroblasts.. *Blood*, **2007**, 110, 2454-2454	2.2	1
214	IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis.. *Blood*, **2009**, 114, 2909-2909	2.2	1
213	Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. *Blood*, **2010**, 116, 3068-3068	2.2	1
212	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. *Blood*, **2010**, 116, 4105-4105	2.2	1
211	A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood*, **2011**, 118, 1746-1746	2.2	1
210	Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,. *Blood*, **2011**, 118, 3850-3850	2.2	1
209	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. *Blood*, **2012**, 120, 1731-1731	2.2	1
208	Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels.. *Blood*, **2012**, 120, 2836-2836	2.2	1
207	Splenectomy for Massive Splenomegaly Associated with Myelofibrosis: Outcomes From 63 Patients At Mayo Clinic.. *Blood*, **2012**, 120, 2848-2848	2.2	1
206	Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. *Blood*, **2013**, 122, 109-109	2.2	1
205	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. *Blood*, **2013**, 122, 1582-1582	2.2	1

204	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. *Blood*, **2013**, 122, 2821-2821	2.2	1
203	Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib. *Blood*, **2013**, 122, 2830-2830	2.2	1
202	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. *Blood*, **2013**, 122, 4049-4049	2.2	1
201	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. *Blood*, **2015**, 126, 1599-1599	2.2	1
200	Spectrum of Mutations Associated with Hereditary Erythrocytosis. *Blood*, **2015**, 126, 2140-2140	2.2	1
199	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. *Blood*, **2015**, 126, 2801-2801	2.2	1
198	Peripheral Blood JAK2V617F Quantitative Assessment in Clinical Practice: Correlations Between Allele Burden and Clinical Phenotype. *Blood*, **2015**, 126, 2819-2819	2.2	1
197	Low Dose, Single Fraction, Whole Lung Irradiation for Extramedullary Hematopoiesis Associated with Myelofibrosis with Myeloid Metaplasia. *Blood*, **2015**, 126, 2820-2820	2.2	1
196	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. *Blood*, **2015**, 126, 350-350	2.2	1
195	Busulfan for the Treatment of Myeloproliferative Neoplasms: The Mayo Clinic Experience. *Blood*, **2015**, 126, 4078-4078	2.2	1
194	Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. *Blood*, **2016**, 128, 3115-3115	2.2	1
193	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. *Blood*, **2016**, 128, 4248-4248	2.2	1
192	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. *Blood*, **2016**, 128, 948-948	2.2	1
191	Is Hydroxyurea Leukemogenic in Essential Thrombocythemia?. *Blood*, **1998**, 92, 1459-1461	2.2	1
190	Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera. *Blood*, **2021**, 138, 1499-1499	2.2	1
189	Cerebral Venous Thrombosis and Myeloproliferative Neoplasms: A Three-Center Study of 74 Consecutive Cases. *Blood*, **2021**, 138, 1493-1493	2.2	1
188	Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms. *Blood*, **2021**, 138, 3651-3651	2.2	1
187	Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. *Blood*, **2000**, 96, 1582-1584	2.2	1

186	A Phase I Trial of Autologous Dendritic Cell Therapy for Chronic Myelogenous Leukemia.. *Blood*, **2004**, 104, 2931-2931	2.2	1
185	Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.. *Blood*, **2007**, 110, 556-556	2.2	1
184	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). *Blood*, **2019**, 134, 4182-4182	2.2	1
183	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.. *Blood*, **2009**, 114, 925-925	2.2	1
182	DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status. *Blood*, **2010**, 116, 4104-4104	2.2	1
181	A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia. *Blood*, **2010**, 116, 4109-4109	2.2	1
180	Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. *Blood*, **2011**, 118, 1752-1752	2.2	1
179	Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort. *Blood*, **2012**, 120, 1729-1729	2.2	1
178	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. *American Journal of Hematology*, **2020**, 95, E31-E34	7.1	1
177	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. *Blood Cancer Journal*, **2021**, 11, 46	7	1
176	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. *Blood Cancer Journal*, **2021**, 11, 54	7	1
175	Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. *British Journal of Haematology*, **2021**, 195, 133-137	4.5	1
174	Mutations and prognosis in myeloproliferative neoplasms. *Leukemia and Lymphoma*, **2019**, 60, 1112-1113	3.9	1
173	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. *British Journal of Haematology*, **2021**, 195, 413-416	4.5	1
172	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, 1450-1460	7.1	1
171	Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: A review **1998**, 59, 161		1
170	Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia. *Seminars in Hematology*, **1999**, 36, 3-8	4	1
169	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.. *Blood Cancer Journal*, **2022**, 12, 44	7	1

168	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.. *American Journal of Hematology*, **2022**,	7.1	1
167	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".. *Blood Cancer Journal*, **2022**, 12, 55	7	1
166	Myeloproliferative neoplasms - a global view.. *British Journal of Haematology*, **2022**,	4.5	1
165	Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. *Blood Cancer Journal*, **2018**, 8, 8	7	0
164	The granulocyte connection in MPD-associated thrombosis. *Blood*, **2007**, 109, 2270-2271	2.2	0
163	Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience.. *American Journal of Hematology*, **2022**,	7.1	0
162	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. *Blood*, **2018**, 132, 4301-4301	2.2	0
161	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. *Blood*, **2011**, 118, 1759-1759	2.2	0
160	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. *Blood*, **2011**, 118, 460-460	2.2	0
159	A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. *Blood*, **2021**, 138, 238-238	2.2	0
158	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. *Blood*, **2021**, 138, 3657-3657	2.2	0
157	A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis. *Blood*, **2021**, 138, 1498-1498	2.2	0
156	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. *Blood*, **2021**, 138, 3368-3368	2.2	0
155	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. *American Journal of Hematology*, **2021**, 97, E62	7.1	0
154	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. *Blood*, **2021**, 138, 3691-3691	2.2	0
153	A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. *American Journal of Hematology*, **2021**, 96, E464-E468	7.1	0
152	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. *Blood*, **2016**, 128, 1987-1987	2.2	0
151	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. *Blood*, **2016**, 128, 5534-5534	2.2	0

150	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. *Blood Cancer Journal*, **2021**, 11, 122	7	0
149	Development and application of novel immunoassays for eosinophil granule major basic proteins to evaluate eosinophilia and myeloproliferative disorders. *Journal of Immunological Methods*, **2021**, 493, 113015	2.5	0
148	Current Management of Chronic Neutrophilic Leukemia. *Current Treatment Options in Oncology*, **2021**, 22, 59	5.4	0
147	Genetic predictors of response to specific drugs in primary myelofibrosis. *Blood Cancer Journal*, **2018**, 8, 120	7	0
146	Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFR□ Mutation. *Acta Haematologica*, **2018**, 140, 67-70	2.7	0
145	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.. *Leukemia Research*, **2022**, 106818	2.7	0
144	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.. *American Journal of Hematology*, **2022**,	7.1	0
143	Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy.. *American Journal of Ophthalmology Case Reports*, **2022**, 26, 101554	1.3	0
142	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. *American Journal of Hematology*, **2018**, 93, E144-E146	7.1	
141	A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. *American Journal of Hematology*, **2018**, 93, E103-E107	7.1	
140	JAK2V617F: more than a clonal marker?. *Leukemia and Lymphoma*, **2009**, 50, 154-5	1.9	
139	Response: Capturing variables with prognostic relevance in development of a new scoring system for primary myelofibrosis. *Blood*, **2010**, 115, 745-746	2.2	
138	Breast peau d'orange from large cell lymphoma. *Mayo Clinic Proceedings*, **2004**, 79, 187	6.4	
137	Mutant Kit: thwarting the message down below. *Blood*, **2005**, 105, 2240-2241	2.2	
136	A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015. *Blood*, **2020**, 136, 48-48	2.2	
135	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. *Blood*, **2020**, 136, 44-44	2.2	
134	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. *Blood*, **2020**, 136, 43-44	2.2	
133	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. *Blood*, **2020**, 136, 35-36	2.2	

132	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. *Blood*, **2020**, 136, 30-31	2.2
131	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. *Blood*, **2020**, 136, 19-20	2.2
130	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.. *Blood Cancer Journal*, **2022**, 12, 12	7
129	High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases. *Blood*, **2021**, 138, 1492-1492	2.2
128	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. *Blood*, **2021**, 138, 1267-1267	2.2
127	Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases. *Blood*, **2021**, 138, 3629-3629	2.2
126	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 2592-2592	2.2
125	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 3684-3684	2.2
124	Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2021**, 138, 1470-1470	2.2
123	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). *Blood*, **2021**, 138, 1096-1096	2.2
122	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. *Blood*, **2021**, 138, 3377-3377	2.2
121	The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events. *Blood*, **2021**, 138, 3630-3630	2.2
120	Clinical and Laboratory Correlative Studies of Neutrophil PRV-1 Expression: A Prospective Study in 141 Subjects.. *Blood*, **2004**, 104, 1519-1519	2.2
119	Allogeneic Stem Cell Transplantation (SCT) in Untreated First Relapse or Following Re-Induction Chemotherapy for Patients with Acute Myeloid Leukemia (AML).. *Blood*, **2004**, 104, 5143-5143	2.2
118	Somatic Point Mutations in RUNX1/CBFA2/AML1 Are Common in High-Risk Myelodysplastic Syndrome, but Not in Myelofibrosis with Myeloid Metaplasia.. *Blood*, **2004**, 104, 2438-2438	2.2
117	Acquired Pure Red Cell Aplasia Associated with Clonal T-Cell Receptor (TCR) Gene Rearrangements with and without Pathologic Features of T-Cell Large Granular Lymphocytic Leukemia (T-LGLL).. *Blood*, **2004**, 104, 2819-2819	2.2
116	Neutrophil and Eosinophil PRV-1 Expression in Atypical Myeloproliferative Disorders.. *Blood*, **2004**, 104, 1521-1521	2.2
115	Cytogenetic Profile, JAK2V617F Mutational Status, and Response to Drug Therapy in Myelofibrosis with Myeloid Metaplasia.. *Blood*, **2005**, 106, 2591-2591	2.2

114	Presence of Unfavorable Cytogenetic Abnormalities Is the Strongest Predictor of Poor Survival in Secondary Myelofibrosis.. *Blood*, **2005**, 106, 2585-2585	2.2
113	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2005**, 106, 5420-5420	2.2
112	Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. *Blood*, **2005**, 106, 2590-2590	2.2
111	Microcytosis in Myelofibrosis with Myeloid Metaplasia: Prevalence and Clinical Correlates.. *Blood*, **2005**, 106, 4947-4947	2.2
110	Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML).. *Blood*, **2005**, 106, 5422-5422	2.2
109	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. *Blood*, **2006**, 108, 116-116	2.2
108	Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders.. *Blood*, **2006**, 108, 661-661	2.2
107	The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR-□-Expressing Cells through Caspase-Dependent Cleavage of MCL-1.. *Blood*, **2006**, 108, 4882-4882	2.2
106	Efficacy of Conventional Cytogenetics and FISH for EGR1 To Detect Deletion 5q in Hematological Disorders and To Assess Response to Treatment with Lenalidomide.. *Blood*, **2006**, 108, 2351-2351	2.2
105	Monocytosis Is an Independent Risk Factor for Survival in Agnogenic Myeloid Metaplasia.. *Blood*, **2006**, 108, 3629-3629	2.2
104	Alemtuzumab (CAMPATH-1H) Is Effective Therapy for Hypereosinophilic Syndrome (HES).. *Blood*, **2006**, 108, 4902-4902	2.2
103	Additional Cytogenetic Abnormalities and/or Philadelphia Chromosome Metaphase Mosaicism Might Adversely Influence Survival and Imatinib Response in Chronic Myeloid Leukemia.. *Blood*, **2006**, 108, 4783-4783	2.2
102	All-Trans Retinoic Acid Syndrome Mimicking ST Segment Elevation Myocardial Infarction.. *Blood*, **2006**, 108, 4571-4571	2.2
101	□diopathic□Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFRA Status, and Clinical Course.. *Blood*, **2006**, 108, 2701-2701	2.2
100	Platelet Count Is an IPSS-Independent Risk Factor Predicting Survival in Refractory Anemia with Ringed Sideroblasts.. *Blood*, **2007**, 110, 2455-2455	2.2
99	Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.. *Blood*, **2007**, 110, 3545-3545	2.2
98	The Presence of the JAK2V617F Mutation in Primary Myelofibrosis and Its Allele Burden in Polycythemia Vera Predict Chemosensitivity to Hydroxyurea.. *Blood*, **2007**, 110, 3539-3539	2.2
97	Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.. *Blood*, **2007**, 110, 3504-3504	2.2

96	Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥10 g/dL.. *Blood*, **2007**, 110, 3555-3555	2.2
95	Peripheral Blood Cytogenetic Studies in Myelofibrosis: Overall Yield and Comparison with Bone Marrow Cytogenetic Studies. *Blood*, **2007**, 110, 1547-1547	2.2
94	Low JAK2V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival.. *Blood*, **2007**, 110, 676-676	2.2
93	Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis.. *Blood*, **2007**, 110, 2550-2550	2.2
92	JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients.. *Blood*, **2007**, 110, 3191-3191	2.2
91	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. *Blood*, **2018**, 132, 3037-3037	2.2
90	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. *Blood*, **2018**, 132, 4300-4300	2.2
89	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. *Blood*, **2018**, 132, 3034-3034	2.2
88	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. *Blood*, **2018**, 132, 1761-1761	2.2
87	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. *Blood*, **2018**, 132, 4287-4287	2.2
86	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. *Blood*, **2018**, 132, 582-582	2.2
85	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. *Blood*, **2018**, 132, 1767-1767	2.2
84	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. *Blood*, **2018**, 132, 4344-4344	2.2
83	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. *Blood*, **2018**, 132, 3050-3050	2.2
82	Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients. *Blood*, **2018**, 132, 5457-5457	2.2
81	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. *Blood*, **2018**, 132, 3033-3033	2.2
80	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. *Blood*, **2018**, 132, 4291-4291	2.2
79	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. *Blood*, **2018**, 132, 3036-3036	2.2

78	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. *Blood*, **2018**, 132, 3100-3100	2.2
77	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. *Blood*, **2018**, 132, 2689-2689	2.2
76	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. *Blood*, **2018**, 132, 3044-3044	2.2
75	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. *Blood*, **2018**, 132, 1771-1771	2.2
74	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. *Blood*, **2019**, 134, 3005-3005	2.2
73	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). *Blood*, **2019**, 134, 5441-5441	2.2
72	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. *Blood*, **2019**, 134, 1697-1697	2.2
71	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. *Blood*, **2019**, 134, 3863-3863	2.2
70	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. *Blood*, **2019**, 134, 1710-1710	2.2
69	Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. *Blood*, **1990**, 75, 1770-1773	2.2
68	The 5q- syndrome: a single-institution study of 43 consecutive patients. *Blood*, **1993**, 81, 1040-1045	2.2
67	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). *Blood*, **2015**, 126, 4067-4067	2.2
66	Arterial Versus Venous Events in Essential Thrombocythemia and Their Impact on Overall and Thrombosis Free Survival. *Blood*, **2015**, 126, 1611-1611	2.2
65	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. *Blood*, **2015**, 126, 4062-4062	2.2
64	Molecular Correlates of Anemia in Primary Myelofibrosis. *Blood*, **2015**, 126, 4068-4068	2.2
63	CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value. *Blood*, **2015**, 126, 2802-2802	2.2
62	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. *Blood*, **2015**, 126, 2875-2875	2.2
61	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2015**, 126, 2864-2864	2.2

60	Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. *Blood*, **2015**, 126, 2805-2805	2.2
59	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. *Blood*, **2015**, 126, 2882-2882	2.2
58	Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia. *Blood*, **2015**, 126, 4055-4055	2.2
57	Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. *Blood*, **2016**, 128, 3129-3129	2.2
56	Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. *Blood*, **2016**, 128, 5541-5541	2.2
55	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. *Blood*, **2016**, 128, 300-300	2.2
54	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. *Blood*, **2016**, 128, 4259-4259	2.2
53	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1988-1988	2.2
52	The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities. *Blood* , **2016**, 128, 5542-5542	2.2
51	Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1989-1989	2.2
50	The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia. *Blood*, **2016**, 128, 3120-3120	2.2
49	A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT).. *Blood*, **2009**, 114, 3891-3891	2.2
48	Myeloproliferative Neoplasms: Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis147-156	
47	Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients. *Blood*, **2010**, 116, 5060-5060	2.2
46	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients. *Blood*, **2010**, 116, 4095-4095	2.2
45	Refined Cytogenetic Risk Categorization for Overall and Leukemia-Free Survival In Primary Myelofibrosis: A Single Center Study of 433 Patients. *Blood*, **2010**, 116, 4122-4122	2.2
44	Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients. *Blood*, **2010**, 116, 5053-5053	2.2
43	Monosomal Karyotype In Primary Myelofibrosis Is Prognostically Worse Than Otherwise Unfavorable Karyotype. *Blood*, **2010**, 116, 3069-3069	2.2

42	Monosomal Karyotype In Myelodysplastic Syndromes, with or without Monosomy 7 or 5, Is Prognostically Worse Than An Otherwise Complex Karyotype. *Blood*, **2010**, 116, 2918-2918	2.2
41	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Blood*, **2010**, 116, 4009-4009	2.2
40	Myeloproliferative Neoplasms47-61	
39	Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases. *Blood*, **2011**, 118, 2806-2806	2.2
38	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. *Blood*, **2011**, 118, 3795-3795	2.2
37	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. *Blood*, **2011**, 118, 3803-3803	2.2
36	Prognostic Irrelevance of Vitamin D Insufficiency in Myeloproliferative Neoplasms and De Novo Myelodysplastic Syndromes. *Blood*, **2011**, 118, 5158-5158	2.2
35	Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients,. *Blood*, **2011**, 118, 3846-3846	2.2
34	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. *Blood*, **2011** , 118, 3833-3833	2.2
33	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. *Blood*, **2011**, 118, 1756-1756	2.2
32	Inhibition of AKT Signaling Potently Inhibits the Growth of JAK and MPL-Mutant Cells in the Myeloproliferative Neoplasms In Vitro and In Vivo,. *Blood*, **2011**, 118, 3862-3862	2.2
31	Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm. *Blood*, **2011**, 118, 5148-5148	2.2
30	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. *Blood*, **2011**, 118, 971-971	2.2
29	Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates. *Blood*, **2011**, 118, 5154-5154	2.2
28	CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts. *Blood*, **2011**, 118, 2807-2807	2.2
27	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. *Blood*, **2011**, 118, 1751-1751	2.2
26	Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response. *Blood*, **2012**, 120, 1751-1751	2.2
25	Polycythemia Vera and Chronic Idiopathic Myelofibrosis CD34+ Cells Preferentially Traffic to Splenic Niches. *Blood*, **2012**, 120, 1750-1750	2.2

24	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. *Blood*, **2012**, 120, 1711-1711	2.2
23	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with □1% Ring Sideroblasts.. *Blood*, **2012**, 120, 2803-2803	2.2
22	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. *Blood*, **2012**, 120, 1726-1726	2.2
21	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. *Blood*, **2012**, 120, 3790-3790	2.2
20	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. *Blood*, **2012**, 120, 430-430	2.2
19	Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2012**, 120, 423-423	2.2
18	Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis.. *Blood*, **2012**, 120, 2831-2831	2.2
17	Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. *Blood*, **2012**, 120, 2852-2852	2.2
16	The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. *Blood*, **2012**, 120, 1742-1742	2.2
15	Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.. *Blood*, **2012**, 120, 2849-2849	2.2
14	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. *Blood*, **2013**, 122, 1587-1587	2.2
13	Serum Ferritin Level At Referral Provides Independent Prognostic Information For Overall Survival In Primary Myelofibrosis. *Blood*, **2013**, 122, 2824-2824	2.2
12	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. *Blood*, **2013**, 122, 4060-4060	2.2
11	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. *Blood*, **2013**, 122, 4048-4048	2.2
10	Masked Polycythemia Vera (mPV): Results Of An International Study. *Blood*, **2013**, 122, 1581-1581	2.2
9	Pruritus In Primary Myelofibrosis: Treatment Attempts, Response and Outcomes. *Blood*, **2013**, 122, 4081-4081	2.2
8	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. *Blood*, **2013**, 122, 5000-5000	2.2
7	Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis. *American Journal of Hematology*, **2016**, 91, E6-7	7.1

6	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. *Leukemia Research*, **2019**, 87, 106264	2.7
5	Calculator-free point-of-care prognostication in myelodysplastic syndromes. *American Journal of Hematology*, **2019**, 94, E99-E101	7.1
4	Introduction: overview of chronic myeloproliferative disorders. *Seminars in Hematology*, **1999**, 36, 1-2	4
3	The recent advances in classic BCR-ABL-negative myeloproliferative disorders. *Clinical Advances in Hematology and Oncology*, **2007**, 5, 113-5	0.6
2	Myeloproliferative neoplasms141-154	
1	A Man with Progressive Effort Intolerance and Splenomegaly393-399	